Literature DB >> 3653227

The pharmacokinetics of yohimbine in man.

J A Owen1, S L Nakatsu, J Fenemore, M Condra, D H Surridge, A Morales.   

Abstract

The kinetic disposition of yohimbine was examined in eight young male subjects following a single oral dose of 10 mg yohimbine hydrochloride. The drug was rapidly absorbed (absorption half-time 0.17 +/- 0.11 h) and rapidly eliminated from the plasma (elimination half-life 0.60 +/- 0.26 h). This clearance of yohimbine from plasma was constant over approximately 10 elimination half-lives, suggesting that distribution into a second pharmacokinetically distinct compartment was not responsible for the rapid decline in plasma yohimbine levels. Urinary excretion and the partitioning of the drug into red blood cells (RBC) was investigated. In the 24 h following oral administration of the drug, virtually no yohimbine was eliminated in the urine (0.35 +/- 0.50% of the administered dose). Furthermore, only 20% of blood-borne yohimbine was located in RBC. These results suggest that yohimbine is eliminated primarily through metabolism since the rapid plasma clearance of yohimbine was not the result of renal elimination or sequestration by RBC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653227     DOI: 10.1007/BF02455991

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Yohimbine as an autonomic test drug.

Authors:  G HOLMBERG; S GERSHON; L H BECK
Journal:  Nature       Date:  1962-03-31       Impact factor: 49.962

2.  Autonomic and psychic effects of yohimbine hydrochloride.

Authors:  G HOLMBERG; S GERSHON
Journal:  Psychopharmacologia       Date:  1961

3.  High-performance liquid chromatography on small particle silica gel.

Authors:  R E Majors
Journal:  Anal Chem       Date:  1972-09-01       Impact factor: 6.986

4.  Diagnosis and management of "endocrine impotence".

Authors:  A J Cooper
Journal:  Br Med J       Date:  1972-04-01

5.  Distribution and metabolism of tritiated yohimbine in mice.

Authors:  A K Ho; D B Hoffman; S Gershon; H H Loh
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-12

6.  Studies on absorption, excretion, and metabolism of 3H-reserpine in man.

Authors:  A R Maass; B Jenkins; Y Shen; P Tannenbaum
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

7.  Pharmacokinetics of a combination of raubasine, dihydroergocristine and dihydroergotamine in dogs and human beings.

Authors:  A Marzo; P Ghirardi; M A Parenti; L Merlo; G Marchetti; L Cavalca; E Omboni; T Pignataro; A Ligresti
Journal:  Farmaco Prat       Date:  1981-04

8.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

Review 9.  The biological fate of reserpine.

Authors:  R E Stitzel
Journal:  Pharmacol Rev       Date:  1976-09       Impact factor: 25.468

Review 10.  Sexual dysfunction associated with diabetes mellitus.

Authors:  A J Wabrek
Journal:  J Fam Pract       Date:  1979-04       Impact factor: 0.493

View more
  16 in total

1.  Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.

Authors:  D M Vanags; S E Rodgers; E M Duncan; J V Lloyd; F Bochner
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.

Authors:  H Bagheri; L Schmitt; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

3.  Overdose of yohimbine.

Authors:  S Varkey
Journal:  BMJ       Date:  1992-02-29

4.  Yohimbine bioavailability in humans.

Authors:  S K Guthrie; M Hariharan; L J Grunhaus
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers.

Authors:  J Galitzky; D Rivière; M A Tran; J L Montastruc; M Berlan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  α2-Adrenergic blockade rescues hypoglossal motor defense against obstructive sleep apnea.

Authors:  Gang Song; Chi-Sang Poon
Journal:  JCI Insight       Date:  2017-02-23

7.  Yohimbine increases human salivary secretion.

Authors:  E Chatelut; Y Rispail; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

8.  Hypertensive urgency: an important aetiology of rebound hypertension.

Authors:  John Malaty; Irene A Malaty
Journal:  BMJ Case Rep       Date:  2014-10-21

9.  Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine.

Authors:  M Berlan; R Le Verge; J Galitzky; P Le Corre
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

10.  Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.

Authors:  H Bagheri; P Picault; L Schmitt; G Houin; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.